Advanced search
Publication Cover
Archives of Andrology
Journal of Reproductive Systems
Volume 49, 2003 - Issue 1
Journal homepage
238
Views
0
CrossRef citations to date
0
Altmetric
Research Article

ERECTILE DYSFUNCTION: CURRENT CONCEPTS AND FUTURE DIRECTIONS

M. MONGA Department of Urologic Surgery, University of Minnesota, Minneapolis, Minnesota, USA
&
M. RAJASEKARAN Division of Urology, University of California, San Diego, California, USA
Pages 7-17 | Published online: 09 Jul 2009

  • Alilain W, Pagnon V, Rajasekaran M (2002): Ex vivo expression of vascular endothelial growth factor in rabbit clitoral smooth muscle cells and its role in cell proliferation. J Urol 167(Suppl), Abst 315.
  • Arver S, Dobs AS, Meikle AW et al (1996): Improvement of sexual function in testosterone deficient men treated for 1 year with a permeation-enhanced testosterone transdermal system. J Urol 155:1604.
  • Baumgarner I, Isner JM (2001): Somatic gene therapy in the cardiovascular system. Aunu Rev Physiol 63:427-450.
  • Berger RE, Rothman I, Rigaud G (1994): Nonvascular causes of impotence. In: Bennett AH, ed. Importance. Philadelphia: WB Saunders.
  • Buvat J, Lemaire A (1997): Endocrine screening in 1022 men with erectile dysfunction: clinical significance and cost-effective strategy. J Urol 158:1764.
  • Chamness SL, Ricker DD, Crone JK, Dembeck CL, Maguire MP, Burnett AL, Chang TSK (1995): The effect of androgen on nitric oxide synthase (NOS) activity in the male reproductive tract of rat. Fertil Steril 63:1101.
  • Chitaley K, Wingard CJ, et al (2001): Antagonism of Rho-kinase stimulates rat penile erection via a nitric oxide-independent pathway. Nat Med 7(1):119-122.
  • Dohi Y, Kojima M, Sato K, Luscher TF (1995): Age-related changes in vascular smooth muscle and endothelium. Drugs Aging 7:278.
  • Eardley I (1998): New Oral therapies for the treatment of erectile dysfunction. Br J Urol 81:122.
  • Fallon B (1995): Intracavernous injection therapy for male erectile dysfunction. Urol Clin N Am 22:833.
  • Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB (1994): Importence and its medical and psychosocial correlates: results of the Massachusetts male aging study. J Urol 151:54.
  • Giulano F, Allard J (2002): Apomorphine SL (Uprima): preclinical and clinical experiences learned from the first central nervous system-acting ED drug. Int J Impot Res 14(Suppl 1):S531-S56.
  • Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA (1998): Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 338:1397-1404.
  • Hale T M, Okabe H et al (2001): Antihypertensive drugs induce structural remodeling of the penile vasculature. J Urol 166:739-745.
  • Hinman F (1993): Atlas of Urosurgical Anatomy. Philadelphia: WB Saunders, pp 430-44.
  • Jaffe A, Chen Y, et al (1996): Erectile dysfunction in hypertensive subjects: assessment of potential determinants. Hypertension 28:859-862.
  • Jarow JP, Burnett AL, Geringer AM (1999): Clinical efficacy of sildenafil citrate based on etiology and response to prior treatment. J Urol 162:732.
  • Mellinger BC, Weiss J (1992): Sexual dysfunction in the elderly male. AUA Update Series 11:146.
  • Mills TM, Chitaley K, Wingard CJ, Lewis RW, Webb RC (2001): Effect of Rho-kinase inhibition on vasoconstruction in the penile circulation. J Appl Physiol 91:1269-1273.
  • Monga M, Jain A, Phelps JS (2002): The co-ordinated approach to erectile dysfunction: psychoeducational and pharmacological interventions. J Urol 167(Suppl):A1112.
  • Monga M, Bettencourt R, Barrett-Connor E (2002): A community-based study of erectile dysfunction and sildenafil use: The Rancho Bernardo Study. Urology 59:753-757.
  • Morales A, Johnson B, Heaton JPW, Lundie M (1997): Testosterone supplementation for hypogonadal importence: assessment of biochemical measures and therapeutic outcomes. J Urol 157:849.
  • Muller SC, el-Damanhoury H, Ruth J, Lue TF (1991): Hypertension and importence. Eur Urol 19:29-34.
  • Mukai Y, Shimokawa H, et al (2001): Involvement of Rho-kinase in hypertensive vascular disease: a novel therapeutic target in hypertension. Faseb J 15:1062-1064.
  • Nadig PW (1994): Vacuum therapy and other devices. In: Bennett AH, ed. Impotence. Philadelphia: WB Saunders.
  • Okabe H, Hale TM, et al (1999): The penis is not protected-in hypertension there are vascular changes in the penis which are similar to those in other vascular beds. Int J Impot Res 11:133-140.
  • Padma-Nathan H, Cheung D, Perelman et al (1990): The effects of aging, diabetes and vascular ischemia on the biochemical composition of collagen found in the corpora and tunica of potent and impotent men. Int J Impot Res 2:75.
  • Padma-Nathan H, Hellstrom WJ, Kaiser FE, et al (1997): Treatment of men with erectile dysfunction with transurethral aiprostadil. Medicated Urethral System for Erection Study Group. N Engl J Med 336:1.
  • Porst H (2002): IC351 (tadalafil, Cialis): update on clinical experience. Int J Impot Res 14:57-64.
  • Pryor J (2002): Vardenafil: update on clinical experience. Int J Impot Res 14:65-69.
  • Rajasekaran M, Pagnon V, Monga M (2002): Vasoactive agents induce cytotoxicity in cultured human smooth muscle cells. Urology 59:155-158.
  • Rajasekaran M, Kasyan A, Jain A, Monga M (2002): Altered growth factor expression in the aging penis: Brown-Norway rat model. J Androl 23:393-399.
  • Rajasekaran M, Kasyan A, Monga (2001): Ex vivo expression of vascular endothelial growth factor and its receptors in human penile cavernosal cells. J Androl 22(Suppl):PP023.
  • Raviv G, Vanegas JP, Petein M, Schulman C, et al (1997): Biochemical alterations of the tunica albuginea in importence. J Urol 158:1778.
  • Rees RW, Ralph DJ, Royle M, Moncada S, Cellek S (2001): Y-27632, an inhibitor of Rhokinase, antagonizes noradrenergic contractions in the rabbit and human penile corpus cavernosum. Br J Pharmacol 133:455-458.
  • Roberts E, Fitten LJ (1990): In: Kalim; M, Regelson W, eds. The Biological Role of Dehydroepiandosterone (DHEA). Berlin: de Gruyster, pp 43-63.
  • Rowland DL, Greenleaf W, Mas M, Myers L, Davidson JM (1989): Penile and finger sensory thresholds in young, aging and diabetic men. Arch Sex Behav 18:1.
  • Saenz de Tejada I, Carson M, Morenas A, Goldstein I, Traish AM (1991): Endothelin: localization, synthesis, activity and receptor types in human penile corpus cavernosum. Am J Physiol 261:H1078.
  • Schiavi RC, White D, Mandeli J, Schreiner-Engel P (1993): Hormones and nocturnal tumescence in healthy aging men. Arch Sex Behav 22:207.
  • Seasholtz TM, Zhang T, Morissette MR, Howes AL, Yang AH, Brown JH (2001): Increased expression and activity of RhoA are associated with increased DNA synthesis and reduced p27(Kipl) expression in the vasculature of hypertensive rats. Circ Res 89:488-495.
  • Sexton WJ, Benedict JF, Jarow JP (1998): Comparison of long-term outcomes of penile prosthesis and intracavernosal injection therapy. J Urol 159:811.
  • Somlyo AP, Wu X, et al (1999): Pharmacomechanical coupling: the role of calcium, G-proteins, kinases and phosphatases. Rev Physiol Biochem Pharmacol 134:201-234.
  • Uehata M, Ishizaki T, et al (1997): Calcium sensitization of smooth muscle mediatd by a Rho-associated protein kinase in hypertension. Nature 389(6654):990-994.
  • Weiner CP, Lizasoain I, Baylis SA, Knowles RG, Charles IG, Moncada S (1994): Induction of calcium-dependent nitric oxide synthases by sex hormones. Proc Natl Acad Sci USA 91:5212.
  • Wertherman P, Rajfer J (1997): MUSE therapy: preliminary clinical observations. Urology 50:809-811.
  • White S, Wilkes N, Bernie J, Rajasekaran M (2002): Role of Rho-kinase inhibition in age-related male erectile dysfunction: the Brown-Norway rat model. J Urol 167 (Suppl). Abstract 934.
  • Wilkes N, Bernie J, Rajasekaran M (2002): Hypertension related alterations in male erectile function: spontaneously hypertensive rat model. J Urol 167(Suppl), Abstract 930.
  • Wilkes N, White S, Cosgrove C, Rajasekaran M (2002): Y-27632, an inhibitor of Rho- kinase improves erectile response in male hypertensive rats. J Urol 167(Suppl), Abstract 935.
  • VandenBerg TL, Hellstrom WJG (1997): Individualizing androgen replacement therapy. Contemp Urol 9:25-40.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.